The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
Article in Frontiers in Public Health (April 2024)
The most recent citing publications are shown below. View all 61 publications that cite this research output on Dimensions.
Article in Frontiers in Public Health (April 2024)
Preprint in Research Square (February 2024)
Article in Medicine Advances (December 2023)